Steven Sahn
- The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension studyBy Ulrich Costabel, Carlo Albera, Alan Cohen, Williamson Bradford, Talmadge King, Paul Noble, Steven Sahn, Dominique Valeyre and Roland du BoisUlrich Costabel1Pneumologie/Allergologie, Ruhrlandklinik, Essen, GermanyCarlo Albera2Dipartimento di Scienze Cliniche e Biologiche, Università diTorino, Torino, ItalyAlan Cohen3Medical Affairs/Clinical Research, InterMune, Inc., Brisbane, CA, United StatesWilliamson Bradford3Medical Affairs/Clinical Research, InterMune, Inc., Brisbane, CA, United StatesTalmadge King Jr.4Department of Medicine, University of California San Francisco, San Francisco, CA, United StatesPaul Noble5Pulmonary, Allergy, and Critical Care Medicine, Duke University, Durham, NC, United StatesSteven Sahn6Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, SC, United StatesDominique Valeyre7Pneumology, Assistance Publique-Hôpitaux, Paris, FranceRoland du Bois8Medicine, Imperial College, London, United Kingdom
- 6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID)By Steven Nathan, Carlo Albera, Roland du Bois, Williamson Bradford, Ulrich Costabel, Talmadge King, Paul Noble, Steven Sahn and Dominique ValeyreSteven Nathan1Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, United StatesCarlo Albera2Clinical and Biological Sciences, University of Turin, ItalyRoland du Bois3Department of Medicine, Imperial College, London, United KingdomWilliamson Bradford4Clinical Reasearch, InterMune, Inc., Brisbane, CA, United StatesUlrich Costabel5Pneumologie/Allergie, Ruhrlandklinik, Essen, GermanyTalmadge King6Department of Medicine, University of California San Francisco, CA, United StatesPaul Noble7Department of Medicine, Duke University School of Medicine, Durham, NC, United StatesSteven Sahn8Department of Medicine, Medical University of South Carolina, Charleston, SC, United StatesDominique Valeyre9Department of Medicine, Assistance Publique-Hôpitaux, Paris, France
- The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)By Dominique Valeyre, Carlo Albera, Williamson Bradford, Ulrich Costabel, Talmadge King, Paul Noble, Steven Sahn and Roland du BoisDominique Valeyre1Department of Medicine, Assistance Publique-Hôpitaux, Paris, FranceCarlo Albera2Clinical and Biological Sciences, University of Turin, ItalyWilliamson Bradford3Clinical Research, InterMune Inc., Brisbane, CA, United StatesUlrich Costabel4Pneumologie/Allergie, Ruhrlandklinik, Essen, GermanyTalmadge King5Department of Medicine, University of California San Francisco, CA, United StatesPaul Noble6Department of Medicine, Duke University School of Medicine, Durham, NC, United StatesSteven Sahn7Department of Medicine, Medical University of South Carolina, Charleston, SC, United StatesRoland du Bois8Department of Medicine, Imperial College, London, United Kingdom
- Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)By Ulrich Costabel, Carlo Albera, Williamson Bradford, Phil Hormel, Talmadge King, Paul Noble, Steven Sahn, Dominique Valeyre and Roland du BoisUlrich Costabel1Pneumologie/Allegie, Ruhrlandklnik, Essen, GermanyCarlo Albera2Clinical and Biological Sciences, University of Turin, ItalyWilliamson Bradford3Clinical Research, InterMune Inc., Brisbane, CA, United StatesPhil Hormel3Clinical Research, InterMune Inc., Brisbane, CA, United StatesTalmadge King4Department of Medicine, University of California San Francisco, CA, United StatesPaul Noble5Department of Medicine, Duke University School of Medicine, Durham, NC, United StatesSteven Sahn6Department of Medicine, Medical University of South Carolina, Charleston, SC, United StatesDominique Valeyre7Department of Medicine, Assistance Publique-Hôpitaux, Paris, FranceRoland du Bois8Depatment of Medicine, Imperial College, London, United Kingdom
- Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medicationsBy Carlo Albera, Williamson Bradford, Ulrich Costabel, Talmadge King, Paul Noble, Steven Sahn, Dominique Valeyre and Roland du BoisCarlo Albera1Department of Clinical and Biological Sciences, University of Turin, ItalyWilliamson Bradford2Clinical Research, InterMune, Inc., Brisbane, CA, United StatesUlrich Costabel3Pneumologie/Allergologie, Ruhrlandklinik, Essen, GermanyTalmadge King4Department of Medicine, University of California San Francisco, United StatesPaul Noble5Department of Medicine, Duke University School of Medicine, Durham, NC, United StatesSteven Sahn6Department of Medicine, Medical University of South Carolina, Charleston, SC, United StatesDominique Valeyre7Department of Medicine, Assistance Publique-Hôpitaux, Paris, FranceRoland du Bois8Department of Medicine, Imperial College, London, United Kingdom
- Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)By Talmadge King, Williamson Bradford, Socorro Castro-Bernardini, Elizabeth Fagan, Ian Glaspole, Marilyn Glassberg, Eduard Gorina, Peter Hopkins, David Kardatzke, Lisa Lancaster, David Lederer, Steven Nathan, Carlos Pereira, Steven Sahn, Robert Sussman, Jeffrey Swigris and Paul NobleTalmadge King1Medicine, University of California, San Francisco, San Francisco, CA,Williamson Bradford2Clinical Research, Intermune Inc, Brisbane, CA,Socorro Castro-Bernardini3Neumocare, Clínica San Borja, Lima, PeruElizabeth Fagan2Clinical Research, Intermune Inc, Brisbane, CA,Ian Glaspole4Medicine, Alfred Hospital, Melbourne, AustraliaMarilyn Glassberg5Medicine, University of Miami Miller School of Medicine, Miami, FL,Eduard Gorina2Clinical Research, Intermune Inc, Brisbane, CA,Peter Hopkins6Medicine, Prince Charles Hospital, Brisbane, QLD, AustraliaDavid Kardatzke2Clinical Research, Intermune Inc, Brisbane, CA,Lisa Lancaster7Medicine, Vanderbilt University Medical Center, Nashville, TN,David Lederer8Medicine, Columbia University Medical Center, New York, NY,Steven Nathan9Medicine, Inova Fairfax Hospital, Falls Church, VA,Carlos Pereira10Medicine, Paulista School of Medicine, Federal University of Sao Paulo, Sao Paolo, BrazilSteven Sahn11Medicine, Medical University of South Carolina, Charleston, SC,Robert Sussman12Medicine, Pulmonary and Allergy Associates, Summit, NJ,Jeffrey Swigris13Medicine, National Jewish Health, Denver, CO,Paul Noble14Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,
- Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim resultsBy Ulrich Costabel, Carlo Albera, Elizabeth Fagan, Williamson Bradford, Talmadge King, Paul Noble, Steven Sahn, Dominique Valeyre and Roland du BoisUlrich Costabel1Pulmonology-Allergology, Ruhrland Klinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen, Essen, GermanyCarlo Albera2Department of Clinical and Biological Sciences, University of Turin, Orbassano (Turin), ItalyElizabeth Fagan3Clinical Science, Intermune, Inc., Brisbane, CA,Williamson Bradford3Clinical Science, Intermune, Inc., Brisbane, CA,Talmadge King4Department of Medicine, University of California, San Francisco, San Francisco, CA,Paul Noble5Department of Medicine, Cedars-Sinai Medical Center, West Hollywood, CA,Steven Sahn6Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC,Dominique Valeyre7Department of Pulmonology, CHU Paris Seine-Saint-Denis - Hôpital Avicenne, Bobigny, FranceRoland du Bois8Emeritus Professor of Respiratory Medicine, Imperial College, London, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
